Skip to main content
Belgian Biosafety Server
Search form
Search
EN
FR
NL
Toggle navigation
Home
Notification procedures
Contained use GMOs/pathogens
Brussels-Capital
Flanders
Wallonia
Supporting tools
Emergency plans GMMs
Some figures
Clinical Trials GMOs
Supporting tools
Database
Some figures
Environmental release GMOs for R&D
Supporting tools
Database
Some figures
Commercialisation medicinal GMOs
Supporting tools
Some figures
Authorisations GMO-human
Authorisations GMO-veterinary
Commercialisation GMOs environment or food/feed
Supporting tools
Some figures
Dossier C/BE/96/01
Regulatory framework
EU framework
Contained use GMMs
Deliberate release GMOs
Decisions releases GMOs
GM Food/Feed
Medicinal GMOs
Worker's protection
Other regulations
Belgian framework
Cooperation agreement
Historical steps
Biosafety Council
SBB
Contained use GMOs/pathogens
Certification and exemptions
Historical perspective
Deliberate release GMOs
Historical background
Scientific assessment
NRL-GMO
Worker's protection
Thematic Areas
Assessment bio-risks
Biosecurity
LAI
Genome editing
Polio eradication
Synthetic biology
Transport
Historical Background
Biological risk classification
Recombinant DNA
GMO - From lab to field
OECD activities
EU GMO Directives
EU GMO definition
FAQ
Events
Upcoming Events
Past Events
Our events
MEACB 2017
Biosafety training (HE2B)
About the SBB
Tasks and activities
Risk assessment
Scientific support
International
Networking activities of the SBB
Research
Communication
Publications
Contact Us
* NEW (25-06-2025) *
genimmune n.v.
glaxo wellcome
Search the database for deliberate release of GM medicinal products
Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
Fulltext search
Search
Reset
EU record number
Title
Company / Sponsor
Treated organism
Genetic modification
B/BE/07/BVW3
A multi-centre phase I study to evaluate the safety and tolerability of a heterologous prime-boost vaccination with INX102-3697 HBV pDNA/INX102-0557 HBV MVA in healthy volunteers and HBeAg+ chronic hepatitis patients
GENimmune N.V.
Humans
Hepatitis B virus polyepitope gene
B/BE/04/BV1
Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
Pfizer, Animal Health Group
cats
gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
Only notified under the "contained use" procedure. Dossier submitted on
13/10/2000
.
A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi
Glaxo Wellcome
Humans
vCP-1452